Aug 3 (Reuters) - POLYPHOR AG POLN.S :
* POLYPHOR ANNOUNCES SECOND POSITIVE DATA SAFETY MONITORING
BOARD
RECOMMENDATION TO CONTINUE PHASE III FORTRESS STUDY WITHOUT
MODIFICATIONS
* STUDY WILL COMPRISE A TOTAL OF 384 PATIENTS WITH HER2
NEGATIVE
MBC, WITH AT LEAST 320 PATIENTS RECEIVING THIRD OR SUBSEQUENT
LINE AND 64 PATIENTS RECEIVING SECOND LINE CHEMOTHERAPY
* SUBJECT TO DATA POLYPHOR MAY BE ABLE TO SUBMIT A FILING
FOR
ACCELERATED APPROVAL APPROXIMATELY SIX MONTHS AFTER RECRUITMENT
IS COMPLETED
* FULL APPROVAL WOULD BE BASED ON MAGNITUDE OF PROGRESSION
FREE
SURVIVAL (PFS) ON BLINDED INDEPENDENT REVIEW, SUPPORTED BY AN
OVERALL SURVIVAL TREND FAVORING BALIXAFORTIDE ARM AND A
FAVORABLE RISK-BENEFIT PROFILE
Source text for Eikon: ID:nEQbP7J6va
Further company coverage: POLN.S
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))